PartnershipUpdated on 10 April 2026
R&D collaboration- biocatalysis
About
Caravel is interested in partnerships or paid research deals with companies that would benefit from producing and/or engineering biocatalysts that are robust, reusable, endotoxin-free and amenable to use in harsher conditions (high temperatures, extremely high or low pHs). Caravels platform involves loading a target protein on the surface of bacterial spores- the most stable form of life on earth. This enables properties that are extended to the displayed protein that otherwise require a greater amount of upfront work for enzyme discovery. Our platform has already achieved an 18 month milestone in 6 months for a carbon capture project with an industrial partner.
On the discovery side, our platform enables screening of up to 10^6 variants a day, thereby speeding up current discovery campaigns. Beyond this, Caravel is also working on incorporation of non-standard amino acids into proteins that enable higher catalytic rates, increased stability and new chemistries.
Organisation
Similar opportunities
Expertise
André Soares
Business Developer at LxBio Pharmaceuticals
Lisbon, Portugal
Partnership
Partnering for AI-Driven RNA-Targeting Therapeutics (ASOs & Small Molecules)
Alex Gavryushkin
Founder & CEO at Fold AI
Sydney, Australia
Expertise
- Healthcare
- Biotech, Pharma and Cosmetics
Sonia Thomson
Communication specialist at Biotechnet Switzerland
Muttenz, Switzerland